Morning briefAfternoon brief
afternoon

S&P 500 falls 0.58% to 7,673.52 as a Novartis trial miss cuts health care 2.52%

Health care fell 2.52% on the Novartis Lp(a) miss while Brent added 3.15% to US$99.31 and INTC.US rose 9.05%

Bearish4 min readBy Swingfolio Research

At a glance

S&P 5007,674-0.58%
NASDAQ26,421-0.32%
Dow52,786-1.18%
VIX15.72+2.75%
Russell 20002,960-0.52%
US Dollar98.86-0.32%
US 10Y4.806+0.46%

Top gainers

  • ROIV.USRoivant Sciences+18.75%
  • SFTBY.USSoftBank Group+17.73%
  • SEI.USSolaris Energy Infrastructure+16.29%
  • SMR.USNuScale Power+15.26%
  • AXTI.USAXT Inc+12.85%

Top losers

  • DYN.USDyne Therapeutics-16.35%
  • GPCR.USStructure Therapeutics-14.70%
  • NVS.USNovartis AG ADR-13.93%
  • HWM.USHowmet Aerospace-10.70%
  • AMGN.USAmgen-10.08%

S&P 500 falls 0.58% to 7,673.52 as a Novartis trial miss cuts health care 2.52%

S&P 500 close: 7,673.52 (-0.58%) Sentiment: bearish

The S&P 500 closed at 7,673.52 on 8 September 2026, down 0.58%, as health care fell 2.52% after Novartis reported that its Lp(a) drug pelacarsen missed in a late stage study. NVS.US lost 13.93% and pulled AMGN.US down 10.08%, because Amgen's olpasiran targets the same lipoprotein. Brent crude added 3.15% to US$99.31 after Houthi strikes halted operations at Saudi energy sites, two days before the August PPI print.

What moved the index

  • Health care: XLV -2.52% against roughly 9% index weight, worth about 23 bps of the 58 bps decline. Novartis pelacarsen missed its endpoint, and its del-desiran myotonic dystrophy study showed no significant improvement over placebo. SYK.US fell 8.81% on its own catalyst: management flagged peripheral vascular supply constraints running into Q4.
  • Financials: XLF -1.38% against roughly 13% weight, about 18 bps. Rotation out of the sector ahead of PPI on 10 September, CPI on 11 September, and the 15 to 16 September FOMC.
  • Cyclicals and defensives: consumer discretionary -0.80%, materials -0.95%, staples -0.66%, communication services -0.46%, industrials -0.48%. Roughly 35% of the index combined, about 22 bps.
  • Offsetting: technology +0.32% (about 11 bps), energy +1.11% (4 bps), utilities +0.86% (2 bps), together about 17 bps of lift.

Together those account for about 46 bps of the 58 bps index move. The residual sits across the whole index. The equal weight S&P 500 (RSP) fell 1.04%, 46 bps worse than the cap weighted index, so the average constituent fell further than the headline print.

Session highlights

  • INTC.US +9.05% to $104.47 after Northland Securities upgraded it to outperform with a $120 target, alongside a media report that Intel plans a third CPU price rise this year of near 10%.
  • IGV -1.83% in a second session of software selling. NOW.US -4.99%, INTU.US -4.14%, CRM.US -3.90%, TEAM.US -6.94%, SHOP.US -7.57%. OpenAI released GPT-6 Astra on 3 September and aimed it at software engineering and professional work.
  • SMH +1.19% while software fell. AVGO.US +2.98%, COHR.US +7.10%, LITE.US +11.04%, VIAV.US +11.16% on the indium phosphide substrate shortage feeding AI optics. NVDA.US fell 2.01%.
  • Brent +3.15% to US$99.31 and WTI +3.03% to US$94.25 at 17:00 ET after Iran aligned Houthi forces struck Saudi energy facilities and wounded more than 70 people. Gold fell 1.71% to US$4,400/oz.
  • Dow -1.18% to 52,786.07 against Nasdaq -0.32% to 26,421.41. AMGN.US closed at $393.17, one of the highest priced Dow members, so its 10.08% fall counted for more in the price weighted average than in the S&P 500.

Sector scorecard

  • Best: energy (XLE +1.11%)
  • Worst: health care (XLV -2.52%)
  • Dispersion (best minus worst): 3.63 pts
  • Technology split inside the sector: SMH +1.19% against IGV -1.83%, a 3.02 pt gap.

Top movers

TickerMoveReason
ROIV.US+18.75%Mosliciguat met Phase 2 endpoints in PH-ILD
SFTBY.US+17.73%Tokyo rally on GPT-6 Astra, 1 trillion yen retail bond priced at 4.75%
SEI.US+16.29%Q3 EBITDA guidance lifted to $110 million to $130 million from $90 million to $105 million
SMR.US+15.26%No company release. Data center power bid across small modular nuclear
AXTI.US+12.85%Indium phosphide shortage bid, alongside LITE.US and COHR.US
DYN.US-16.35%Novartis del-desiran failure hit the same myotonic dystrophy target
GPCR.US-14.70%Aleniglipron and ACCG-2671 obesity data missed expectations
NVS.US-13.93%Pelacarsen missed on Lp(a), del-desiran showed no improvement in DM1
HWM.US-10.70%SpaceX said it will make gas turbine blades in house
AMGN.US-10.08%Olpasiran sits in the same Lp(a) class as pelacarsen

Notable announcements

  • SEI.US raised Q3 adjusted EBITDA guidance by 23% at the midpoint and Q4 by 48% at the midpoint, and added Omega Foundation Services for data center construction work.
  • SYK.US management said peripheral vascular supply constraints run through Q3 and into Q4.
  • SFTBY.US priced a 1 trillion yen retail bond at a 4.75% coupon, the top of the indicated range.
  • HWM.US closed at $231.53 after opening at $242.81 against a $259.27 prior close, on the SpaceX in house blade plan.

After-hours earnings

TTAN.US fell 19.3% after the bell on its fiscal Q2 result, having already closed the regular session down 7.21%. ServiceTitan guided fiscal 2027 revenue to $1.11 billion to $1.12 billion and Q3 operating income to $29 million to $30 million, and said it expects more than 700 enrolled Max locations by year end.

Next session catalysts (ET)

  • Wed 9 Sep, 10:30 : weekly EIA crude inventories, with Brent at a six week high
  • Thu 10 Sep, 08:30 : August PPI
  • Thu 10 Sep, 08:30 : weekly initial jobless claims
  • Fri 11 Sep, 08:30 : August CPI, the last inflation print before the FOMC
  • Tue 15 Sep to Wed 16 Sep : FOMC meeting and rate decision

Context only, not financial advice. Track your own trades with Swingfolio.

Track every trade. Learn from every week.

Swingfolio logs your entries, exits, and R-multiples automatically — so your weekly review writes itself.

Disclaimer

This briefing provides market observations and general information only. It is not personal financial advice and does not take into account your objectives, situation or needs. Past performance is not a reliable indicator of future performance. Consider seeking independent advice before acting on any information presented here.

Prices and market data sourced from EODHD and Yahoo Finance and may be delayed. Swingfolio does not hold an AFS licence and does not provide personal advice. Editorial standards and methodology →